Status
Conditions
About
Primary objective of this study is to identify and describe the clinico-biological and molecular characteristics of tumors with somatic POLE (Polymerase ɛ)/POLD1 mutation identified by molecular biology platforms for all stages and primary sites combined
Full description
The identification of patients to be included will be done directly from the tumor genotyping platforms.
Indeed, they will be the direct source of the identification of all POLE (Polymerase ɛ) mutations.
The platforms will inform the project coordination unit of new cases of mutated cancers as well as the referent investigator, jointly they will be in charge of data entry.
The diagnostic and follow-up data of each patient will be collected prospectively.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Diagnosis made from the date of launch of the cohort and in the previous year
-Age ≥ 18 years
Exclusion criteria
Loading...
Central trial contact
ROSINE GUIMBAUD, PhD.MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal